Skip to main content

USA turu kommentaar

PFE
Why is U.S. vaccine rollout taking longer than expected?

- Nearly 38M vaccine doses were distributed to U.S. states as of
Thursday, according to the CDC, but only about 17.5M have actually been
administered. That means over half of the shipped vaccines are sitting on
shelves across the country. Of the jabs given, 15M have been for a first
dose, while only 2.5M Americans have been given a second round of
Pfizer-BioNTech (PFE, BNTX) or Moderna's (NASDAQ:MRNA) inoculation.
- *What's holding up the rollout? *"We are working closely with Gen.
Gustave Perna (head of logistics in Operation Warp Speed), with the
manufacturers, with the states to understand exactly where the supply
is,"
Dr. Rochelle Walensky, the new director of the CDC, told NBC's *TODAY*.
At least 12 states have reported vaccine shortages, and officials from
San
Francisco and New York warned that they could be completely out of doses
this week. She also said President Biden would also invoke the Defense
Production Act if there were supplies that were needed in vaccine
production, distribution of administration.
- *Quote:* "We need to make sure we titrate the amount of vaccine that
we have, for the people that are eligible (even expand eligibility), so
we
don't have vaccines on the shelves," added Walensky. "We also need to
make
sure there are enough vaccinators out there, including the Commissioned
Health Corps, medical military, retirees, dentists, veterinarians, and
medical and nursing students that are about to graduate. The CDC is also
looking at increasing the sites where people can get vaccinated,
including
community vaccination centers, stadiums, gyms, mobile units, federally
qualified healthcare centers and pharmacies."
- *Thought bubble:* Additional FDA-approved jabs can help boost supply
at a time when COVID deaths across the U.S. are forecast to pass the
half a
million milestone by the end of February. Johnson & Johnson (NYSE:JNJ)
will soon send over safety and efficacy data of its Phase 3 trials,
which appeared to generate a promising antibody response in earlier
assessments. Health officials have high hopes for the one-shot regimen,
which simplifies the process of getting it out to the public.
- *What it means for markets: *Wall Street is hedging against possible
bumps in the U.S. vaccine rollout, according to Reuters, as the CBOE
Volatility Index expiring in March and beyond trades well above the
index's
current levels. Uncertainty over the rollout has also seen the VIX hover
above its long-term average near 20, even as the Dow Jones, S&P 500,
Nasdaq
and Russell 2000 rally to record highs.





|Today, 4:20 AM|17 Comments

Comments

Popular posts from this blog

Nasdaq Balti börsidel algas kauplemine Grenardi Groupi võlakirjadega

Nasdaq Balti börsidel algas kauplemine Grenardi Groupi võlakirjadega. See on märkimisväärne sündmus nii ettevõtte kui ka Balti kapitaliturgude jaoks. Siin on lühike kokkuvõte olulisest: Ettevõte: Grenardi Group Tegevus: Juveelipoodide kett Balti riikides Võlakirjade maht: 12 miljonit eurot Intressimäär: 10% aastas Lunastamistähtaeg: 16. aprill 2027 Investorid: Enamasti Läti investorid (85%), 12% Eestist ja 3% Leedust Noteerimine: Nasdaq Riia börsil Mõned olulised punktid: Grenardi Group on edukalt kaasanud 12 miljonit eurot kapitali avaliku võlakirjapakkumise kaudu. See on ettevõtte kolmas võlakirjaemissioon ja esimene noteerimine reguleeritud börsil. Suur investorite huvi näitab usaldust Grenardi Groupi ja Balti turu vastu. Võlakirjadest saadud raha plaanitakse kasutada ettevõtte kasvatamiseks ja Balti turul konkurentsipositsiooni tugevdamiseks. Grenardi Groupi juht Ģirts Rudzītis ütles: "Oleme avaliku pakkumise tulemustega väga rahul. Täname igaüht neist...

Storent Holding avaldas 2023. aasta auditeeritud aruanded: kasumlik aasta hoolimata ümberhindamisest

Sissejuhatus Storent Holding, mille eelmiseks ärinimeks oli Storent Holdings SIA, avaldas hiljuti oma konsolideeritud ja eraldiseisvad 2023. aasta finantsaruanded. Auditeeritud aruanded näitavad kasumlikku aastat hoolimata ümberhindamisest ja tulumaksueelses kasumis tehtud muudatustest. Aruanne annab ülevaate olulistest sündmustest ja finantstulemustest 2023. aastal ning ettevõtte väljavaadetest 2024. aastaks. Olulised punktid Kasv 2023. aastal: Storent Group saavutas märkimisväärse kasvu, investeerides 13 miljonit eurot uutesse seadmetesse ning jätkates investeeringuid IT-süsteemidesse ja protsesside automatiseerimisse. Ümberhindamisest tingitud muudatused: ettevõtte juhtkond otsustas 2023. aastal muuta püsivara amortisatsiooni arvestusmeetodit, võttes arvesse jääkväärtust. Muudatuste tulemusel kaasnes korrigeerimine tulumaksueelses kasumis. Kasumlikkus: Aasta kogukäive oli 43,8 miljonit eurot, EBITDA 13,7 miljonit eurot ja tulumaksueelne kasum 5,5 miljonit eurot. Uus võlakirja...

What's happening in the commercial real estate

Here's a breakdown of what's happening in the commercial real estate (CRE) market, focusing on office properties and using 1440 Broadway as a case study: Trends in the Office Property Market: The Rise of Remote Work: The COVID-19 pandemic accelerated the adoption of remote and hybrid work models. Many companies are downsizing or re-evaluating their office space needs. This is leading to increased vacancy rates and declining rental income for office properties. Changing Preferences: Businesses rethinking office spaces are now prioritizing flexibility, collaboration spaces, and amenities that create a compelling reason for employees to come to the office. Economic Uncertainty: Rising interest rates and potential economic downturns are making investors and lenders more cautious about commercial real estate investments, including office properties. The Case of 1440 Broadway: Loan Delinquency: The $400 million loan backing 1440 Broadway becoming delinquent highlights...